An update on the medical therapy of advanced metastatic renal cell carcinoma

Stephan Kruck, Axel S. Merseburger, Georgios Gakis, Mario W. Kramer, Arnulf Stenzl, Markus A. Kuczyk

7 Zitate (Scopus)


The effectiveness of multikinase inhibitors in first- and second-line therapy of metastatic renal cell carcinoma (RCC) has been evaluated in various clinical studies. Initial results indicate an increased response rate and a prolonged progression-free survival compared with cytokine-containing therapeutic approaches. The new multitargeted kinase inhibitors sorafenib (Nexavar®/BAY 43-9006) and sunitinib (Sutent®/SUO 11248) interfere mainly with vascular endothelial growth factor and platelet-derived growth factor pathways. Recently, temsirolimus, a specific inhibitor of mammalian target of rapamycin, demonstrated activity in RCC patients with poor prognosis. This review discusses the effectiveness of the most frequently used substances for systemically progressive RCC in consideration of the currently available clinical data.

ZeitschriftScandinavian Journal of Urology and Nephrology
Seiten (von - bis)501-506
PublikationsstatusVeröffentlicht - 2008

Strategische Forschungsbereiche und Zentren

  • Profilbereich: Lübeck Integrated Oncology Network (LION)


Untersuchen Sie die Forschungsthemen von „An update on the medical therapy of advanced metastatic renal cell carcinoma“. Zusammen bilden sie einen einzigartigen Fingerprint.